GE renamed Cytiva upon take-over by Danaher

The acquisition of GE Healthcare Life Sciences by Danaher Corporation creates a giant in contract manufacturing and development. While GE Healthcare Life Sciences, will retain its 7,000 staff and multinational operations, the company will change its name to Cytiva, combining its well-known brands and offerings – ÄKTA, Amersham, HyClone, MabSelect or Whatman – with its new mother company’s platform.

The mission of the newly created CDMO, which is set to generate US$3.3bn in annual revenues, is to grow in the expanding biologicals market. Emmanuel Ligner, President of Cytiva, said, "Our commitment remains to provide patients with life-changing therapies and we will continue to bring innovative technologies to market that improve our customers’ productivity.” The CDMO will not only help companies help outsource their biologics production but also intends to provide services to the scientific community. 

According to Danaher, in 2019, more than 75% of FDA-approved biological therapies  relied on Cytiva technology for manufacturing including the emerging cell and gene therapy market, a field conducting more than 1,000 regenerative medicine studies at global scale.

As the global demand for personalised medicines, and advanced biological therapies continues to grow, the company will rely on its huge capabilities in instrumentation, cell line and process development together with effective production and purification technologies. Cytiva announced it will continue to drive research collaborations, including with the Center for Advanced Biological Innovation and Manufacturing in Boston, Harvard, MIT, university hospitals and industry partners such as Fujifilm Diosynth Biotechnologies and Alexandria Real Estate Equities Inc.Cytiva’s broad portfolio includes well-known brands such as ÄKTA, Amersham, Biacore, FlexFactory, HyClone, MabSelect, Sefia, Whatman, Xcellerex and Xuri.